[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-334697-105":59,"doc-detail-334697-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","targeting-interleukin-13-receptor-2-and-epha2-in-aggressive-breast-cancer-subtypes-with-special-references-to-chimeric-antigen-receptor-t-cell-therapy","Targeting Interleukin-13 Receptor α2 and EphA2 in Aggressive Breast Cancer Subtypes with Special References to Chimeric Antigen Receptor T-Cell Therapy","","Breast cancer (BCA) remains the leading cause of cancer-related mortality among women worldwide. This review examines therapeutic challenges in BCA and focuses on interleukin-13 receptor α2 (IL-13Rα2) and EphA2, highlighting their overexpression and roles in tumor progression, resistance, and poor outcomes in aggressive subtypes such as Her-2-enriched and triple-negative breast cancer. It summarizes the structural and functional biology of these receptors and evaluates how targeting them could enable effective dual antigen CAR-T immunotherapies. ",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/targeting-interleukin-13-receptor-2-and-epha2-in-aggressive-breast-cancer-subtypes-with-special-references-to-chimeric-antigen-receptor-t-cell-therapy/334697/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/targeting-interleukin-13-receptor-2-and-epha2-in-aggressive-breast-cancer-subtypes-with-special-references-to-chimeric-antigen-receptor-t-cell-therapy/334697.png","ImageObject",300,407,{"name":92,"@type":93},"Ava Thompson","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-24","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why are IL-13Rα2 and EphA2 considered promising targets in aggressive breast cancer?","Question",{"text":112,"@type":113},"They are overexpressed in breast cancer, especially aggressive subtypes, and are linked to tumor progression, resistance, and poor prognosis. Their differential expression between normal and malignant tissues supports targeted therapeutic strategies.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does EphA2 contribute to cell signaling relevant to cancer?",{"text":117,"@type":113},"EphA2 is a receptor tyrosine kinase in the Eph family whose primary ligand is ephrin A1. Bidirectional signaling between adjacent cells is altered in pathological contexts, including breast cancer, where EphA2 promotes progression and unfavorable outcomes.",{"name":119,"@type":110,"acceptedAnswer":120},"What is the role of IL-13Rα2 in tumor proliferation and immune evasion?",{"text":121,"@type":113},"IL-13Rα2 is a membrane-associated protein whose expression and signaling are associated with increased proliferation, invasion, metastasis, and cellular survival. Tumor cells can manipulate IL-13Rα2 receptor expression to support tumorigenesis, progression, and immune evasion.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},334697,1790550494,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},1649267921044,"https://us-avatar.wpscdn.com/avatar/1800007509477c92dfb?_k=1786009248482753345","Review  \nTargeting Interleukin-13 Receptor α2 and EphA2 in Aggressive Breast Cancer Subtypes with Special References to Chimeric Antigen Receptor T-Cell Therapy  \nDharambir Kashyap  and Huda Salman *  \nCitation: Kashyap, D.; Salman, H. Targeting Interleukin-13 Receptor α2 and EphA2 in Aggressive Breast Cancer Subtypes with Special References to Chimeric Antigen Receptor T-Cell Therapy. Int. J. Mol. Sci. 2024, 25, 3780. [https://doi.org/](https://doi.org/)[ ](https://doi.org/)[10.3390/ijms25073780](10.3390/ijms25073780)  \nAcademic Editor: Domenico Galati  \nReceived: 15 March 2024  \nRevised: 24 March 2024  \nAccepted: 25 March 2024  \nPublished: 28 March 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \nBrown Center for Immunotherapy, Melvin and Bren Simon Comprehensive Cancer Center, Division of  \nHematology and Oncology, School of Medicine, Indiana University, Indianapolis, IN 46202, USA; [dbir@iu.edu](dbir@iu.edu)  \n* [Correspondence: hsalman@iu.edu](Correspondence: hsalman@iu.edu)  \nAbstract: Breast cancer (BCA) remains the leading cause of cancer-related mortality among women worldwide. This review delves into the therapeutic challenges of BCA, emphasizing the roles of interleukin-13 receptor α2 (IL-13Rα2) and erythropoietin-producing hepatocellular receptor A2  \n(EphA2) in tumor progression and resistance. Highlighting their overexpression in BCA, particularly in aggressive subtypes, such as Her-2-enriched and triple-negative breast cancer (TNBC), we discuss the potential of these receptors as targets for chimeric antigen receptor T-cell (CAR-T) therapies. We examine the structural and functional roles of IL-13Rα2 and EphA2, their pathological significance in BCA, and the promising therapeutic avenues their targeting presents. With an in-depth analysis of current immunotherapeutic strategies, including the limitations of existing treatments and the potential of dual antigen-targeting CAR T-cell therapies, this review aims to summarize potential future novel, more effective therapeutic interventions for BCA. Through a thorough examination of preclinical and clinical studies, it underlines the urgent need for targeted therapies in combating the high mortality rates associated with Her-2-enriched and TNBC subtypes and discusses the potential role of IL-13Rα2 and EphA2 as promising candidates for the development of CAR T-cell therapies.  \nKeywords: triple-negative breast cancer; interleukin-13 receptor α2; EphA2; immunotherapy  \n1. Introduction  \nBreast cancer (BCA) represents the foremost cause of cancer-related mortality after cardiovascular disease among women, accounting for 31%(297,790 cases) of all cancer diagnoses in 2023, followed by lung/bronchus (13%) and colorectal (8%) [1] . The challenges in BCA treatment include therapeutic resistance, the emergence of acquired resistance, and the absence of precise, targetable biomarkers with consistent expression on cancer cells. The interleukin-13 receptor α2 (IL-13Rα2) and the erythropoietin-producing hepatocellular receptor A2 (EphA2) have been identified as playing crucial roles in tumor growth and progression [2,3] . EphA2, a constituent of the Eph kinase subfamily, falls within the receptor tyrosine kinase (RTK) superfamily [4] . Ephrin A1 serves as the primary ligand for EphA2, facilitating cell–cell interactions necessary for the transmission of bidirectional signals between adjacent cells [5] . In cells expressing EphA2, a forward signal is relayed, whereas in those expressing ephrin A1, a reverse signal is conveyed. As such, EphA2 is pivotal for intercellular communication, influencing both normal physiological processes and pathological conditions, including","cbCaihg1UZOAWNoG","https://ap.wps.com/l/cbCaihg1UZOAWNoG","pdf",3739565,21,"English","# Introduction\n## Therapeutic challenges in breast cancer\n## Roles of IL-13Rα2 and EphA2 in tumor progression\n## EphA2 signaling and ephrin A1 interactions\n## IL-13Rα2 expression and IL-13 mediated effects\n## Rationale for targeted immunotherapy and CAR T-cells","[{\"question\":\"Why are IL-13Rα2 and EphA2 considered promising targets in aggressive breast cancer?\",\"answer\":\"They are overexpressed in breast cancer, especially aggressive subtypes, and are linked to tumor progression, resistance, and poor prognosis. Their differential expression between normal and malignant tissues supports targeted therapeutic strategies.\"},{\"question\":\"How does EphA2 contribute to cell signaling relevant to cancer?\",\"answer\":\"EphA2 is a receptor tyrosine kinase in the Eph family whose primary ligand is ephrin A1. Bidirectional signaling between adjacent cells is altered in pathological contexts, including breast cancer, where EphA2 promotes progression and unfavorable outcomes.\"},{\"question\":\"What is the role of IL-13Rα2 in tumor proliferation and immune evasion?\",\"answer\":\"IL-13Rα2 is a membrane-associated protein whose expression and signaling are associated with increased proliferation, invasion, metastasis, and cellular survival. Tumor cells can manipulate IL-13Rα2 receptor expression to support tumorigenesis, progression, and immune evasion.\"}]","Targeting Interleukin-13 Receptor α2 and EphA2 in Aggressive Breast Cancer Subtypes with Special References to Chimeric Antigen Receptor T-Cell Therapy | PDF",1790007925,53]